Santen Pharmaceutical Co Ltd
TSE:4536

Watchlist Manager
Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd
TSE:4536
Watchlist
Price: 1 565.5 JPY -1.85%
Market Cap: 543.3B JPY
Have any thoughts about
Santen Pharmaceutical Co Ltd?
Write Note

Gross Margin
Santen Pharmaceutical Co Ltd

57.9%
Current
59%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
57.9%
=
Gross Profit
175.3B
/
Revenue
302.6B

Gross Margin Across Competitors

Country JP
Market Cap 546.6B JPY
Gross Margin
58%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 755.8B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.1B USD
Gross Margin
69%
Country US
Market Cap 251.8B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.5B USD
Gross Margin
71%
No Stocks Found

Santen Pharmaceutical Co Ltd
Glance View

Market Cap
546.6B JPY
Industry
Pharmaceuticals

Santen Pharmaceutical Co., Ltd., a cornerstone of Japan's robust pharmaceutical industry, has been relentlessly focused on improving eye health worldwide. Founded in 1890, the company began as a modest medicine retailer in Osaka, but over the decades, it has skillfully navigated the evolving healthcare landscape to become a global leader in ophthalmology. Today, Santen's enterprise is intricately woven with innovation and specialization, stretching its influence far beyond its Japanese roots. Its main thrust lies in the research, development, and commercialization of ophthalmic products tackling a comprehensive range of eye disorders, from dry eyes to age-related macular degeneration and glaucoma. By investing significantly in R&D, Santen maintains a robust pipeline of new treatments that continuously feeds into its growing portfolio, ensuring its offerings are at the forefront of medical advancements. Santen's business strategy thrives on leveraging its scientific expertise to not only create but also efficiently bring products to market across various continents. It operates through a well-crafted distribution network that spans Asia, Europe, and North America, tailoring its marketing and regulatory approaches to suit regional healthcare environments. This global footprint allows Santen to capture diverse markets, each with unique demands, thereby enhancing revenue streams. The firm's operational model also includes strategic partnerships and acquisitions, enhancing its research capabilities and expanding its market share to sustain profitability. Santen generates revenue primarily through the sale of innovative ophthalmic prescription drugs and over-the-counter products, supported by its strong relationships with healthcare professionals and continued expansion into emerging markets. The company’s focused strategy and commitment to eye health solutions position it as an indispensable player in the global healthcare industry.

Intrinsic Value
2 317.4 JPY
Undervaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
57.9%
=
Gross Profit
175.3B
/
Revenue
302.6B
What is the Gross Margin of Santen Pharmaceutical Co Ltd?

Based on Santen Pharmaceutical Co Ltd's most recent financial statements, the company has Gross Margin of 57.9%.